Clinical Trial Update: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial update for RYZ101 versus standard of care in patients with inoperable, well-differentiated SSTR-positive gastroenteropancreatic neuroendocrine tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Gastroenteropancreatic Neuroendocrine Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• RYZ101

Snippet

Sponsor: RayzeBio, Inc. | Conditions: GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor | Phase 3 | Status: RECRUITING